LEADER 02400nam  2200337 n 450 
001 9910674381403321
005 20230623153452.0
035   $a(CKB)3800000000216554
035   $a(NjHacI)993800000000216554
035   $a(EXLCZ)993800000000216554
100   $a20230623d2017      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCurrent Knowledge in Thyroid Cancer - From Bench to Bedside /$fDaniela Gabriele Grimm, editor
210  1$aBasel :$cMDPI AG - Multidisciplinary Digital Publishing Institute,$d2017.
215   $a1 online resource (220 pages) $cillustrations
311   $a3-03842-476-5 
330   $aAnnotation In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory. In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer.
606   $aThyroid hormones
615  0$aThyroid hormones.
676   $a612.44
702   $aGrimm$b Daniela Gabriele
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910674381403321
996   $aCurrent Knowledge in Thyroid Cancer ? From Bench to Bedside$92990441
997   $aUNINA

LEADER 01876nas  2200625-a 450 
001 9910145177203321
005 20250512182229.0
011   $a0975-6434
035   $a(OCoLC)64202093
035   $a(CKB)1000000000273101
035   $a(CONSER)--2006265009
035   $a(EXLCZ)991000000000273101
100   $a20060222a19519999  ---         -
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 04$aThe journal of obstetrics and gynecology of India
210   $a[Bombay] $cFederation of Obstetric and Gynaecological Societies of India
210 3 $aNew Delhi $cSpringer India
215   $a1 online resource
300   $aRefereed/Peer-reviewed
311 08$a0971-9202 
517 3 $aJ. obstet. gynecol. India
517 3 $aJOGI
531   $aJOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA
531   $aJ OBSTET GYNAECOL INDIA
531 0 $aJ. obstet. gynecol. India
606   $aObstetrics$vPeriodicals
606   $aGynecology$vPeriodicals
606   $aFemale
606   $aGynecology
606   $aObstetrics
606   $aGynecology$2fast$3(OCoLC)fst00949684
606   $aObstetrics$2fast$3(OCoLC)fst01042994
606   $aGinecologia$2thub
606   $aObstetrícia$2thub
608   $aPeriodical.
608   $aPeriodicals.$2fast
608   $aRevistes electròniques.$2thub
615  0$aObstetrics
615  0$aGynecology
615 02$aFemale.
615 12$aGynecology.
615 12$aObstetrics.
615  7$aGynecology.
615  7$aObstetrics.
615  7$aGinecologia
615  7$aObstetrícia
712 02$aFederation of Obstetric and Gynaecological Societies of India.
906   $aJOURNAL
912   $a9910145177203321
996   $aThe journal of obstetrics and gynecology of India$92251262
997   $aUNINA